SCHEMBL25681985

SCHEMBL25681985

COc1cc(/C=C/C(=O)N2CCC=CC2=O)cc(OC)c1OCCOCCOCCOCCNC(=O)OC(C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.63
TP53 P04637 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
MAPT P10636 2/20 0.63
HSD17B10 Q99714 2/20 0.63
LMNA P02545 2/20 0.63
CYP1A2 P05177 1/20 0.63
HIF1A Q16665 1/20 0.63
PSMB11 A5LHX3 1/20 0.63
PSMA7 O14818 1/20 0.63
NPC1 O15118 1/20 0.63
FOXO3 O43524 1/20 0.63
MITF O75030 1/20 0.63
CYP3A4 P08684 1/20 0.63
PSMB1 P20618 1/20 0.63
PSMA1 P25786 1/20 0.63
PSMA2 P25787 1/20 0.63
PSMA3 P25788 1/20 0.63
PSMA4 P25789 1/20 0.63
PSMB8 P28062 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25681948 1.00 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25681916 1.00 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL173117 0.96 ALDH1A1 (0.66) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL30496625 0.92 ALDH1A1 (0.63) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25238224 0.89 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25279817 0.89 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25288385 0.89 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25240648 0.89 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25282131 0.89 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10
SCHEMBL25288386 0.89 ALDH1A1 (0.68) ALDH1A1TP53SMN1; SMN2MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057963-A1 DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-02-20 US disclosed
WO-2023114455-A1 DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-06-22 WO disclosed
WO-2023114455-A1 DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057963-A1 DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND CDK10, CDK20, CDK9 ALDH1A1 1803/4885TP53 265/4885SMN1; SMN2 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.